Association of Body Mass Index and Cognitive Function in Alzheimer's Disease and Mild Cognitive Impairment.
- Author:
Eun Jeong LIM
1
;
Kang Joon LEE
;
Hyun KIM
Author Information
1. Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea. intuit@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Alzheimer's disease;
Mild cognitive impairment;
Body mass index;
Cognitive decline
- MeSH:
Alzheimer Disease*;
Body Mass Index*;
Cognition Disorders;
Cognition*;
Dementia;
Diagnosis;
Humans;
Longitudinal Studies;
Mild Cognitive Impairment*;
Physical Examination
- From:Korean Journal of Psychosomatic Medicine
2016;24(2):184-190
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This study analyzed the differences of body mass index(BMI) in Korean patients with Alzheimer's diseases(AD), Mild Cognitive Impairment(MCI), and healthy controls to verify whether low BMI is associated with cognitive impairment. Furthermore, this study also sought to examine any association between BMI and Mini Mental State Examination-Korean version(MMSE-K), Clinical Dementia Rating(CDR), and Global Deterioration Scale(GDS). METHODS: A total of 257 subjects were included in the study. History taking, mental status examination, physical examination and neurocognitive function test were carried out for the diagnosis of AD and MCI. The subjects' demographic data and presence of diseases were also surveyed. The overall cognitive function and severity of diseases were assessed using MMSE-K, GDS, and CDR. RESULTS: The order of BMI was found to be healthy controls>MCI>AD, with statistically significant differences among the groups. The order of MMSE-K scores was similar, with healthy controls>MCI>AD in statistically significant differences. The healthy controls had the lowest CDR and GDS scores, and AD patients had the highest scores. There was a significant positive correlation between BMI and MMSE scores(r=0.238, p=0.000). BMI was negatively correlated with CDR(r=−0.174, p=0.008) as well as with GDS(r=−0.233, p=0.000). CONCLUSIONS: Measuring BMI of patients with AD or MCI is expected to be meaningful in that BMI could be a clinical indicator of AD. We expect this to be beneficial for the diagnosis, prevention, and therapeutic approach of AD and also expect large-scale, long-term longitudinal studies to follow.
